MDSC Inhibitor Therapy in Myeloproliferative Neoplasm

Jen Chin Wang; Zayar O

doi:10.4172/jmir.1000129

Journal of Mucosal Immunology Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary
J Mucosal Immunol Res,
DOI: 10.4172/jmir.1000129

MDSC Inhibitor Therapy in Myeloproliferative Neoplasm

Jen Chin Wang¹^* and Zayar O²: ¹Department of Hematology/Oncology, Brookdale University Hospital Medical Center, NewYork, US; ²Department of Medicine, Kingsbrook Jewish Medical Center, NewYork, USA

^*Corresponding Author : Jen Chin Wang, Department of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, NewYork, USA, Email: jcwang0005@Gmail.com

Received Date: Jan 07, 2021 / Accepted Date: Jan 21, 2021 / Published Date: Jan 28, 2021

View PDF Download PDF

Citation: Wang JC, Oo Z. (2021) MDSC Inhibitor Therapy in Myeloproliferative Neoplasm. J Mucosal Immunol Res 5: 129. Doi: 10.4172/jmir.1000129

Copyright: © 2021 Wang JC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.